October 21, 2021 07:07 AM EDT

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

Amber Tong

Just as Avoro Capital’s campaign to derail Merck’s proposed $11.5 billion buyout of Acceleron gains steam, Bristol Myers Squibb is leaning in with some …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump administration reverses lease termination for major FDA quality lab in St. Louis

Judge grants new nationwide block on NIH payment cuts

Live updates: Trump NIH pick Bhattacharya sails through Senate hearing, sidestepping controversy

FDA puts BioNTech’s malaria vaccine on clinical hold

Novo Nordisk slashes Wegovy price by nearly two-thirds for cash-paying patients

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Bris­tol My­ers pledges to sell its Ac­celeron shares as ac­tivist in­vestors cir­cle Mer­ck­'s $11.5B buy­out — re­port

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report